About Axovan
Axovan is a Healthcare company based in Allschwil (Switzerland) founded in 2000, and was acquired by Actelion in September 2003. Drug development company specializing in G Protein-Coupled Receptors (GPCRs) targeting therapeutics. Axovan has raised $23.31 million across 2 funding rounds from investors including Actelion, Atlas Venture and Heidelberg Innovationsfonds Management. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified.
Company details
Axovan AG was a drug development company specializing in G Protein-Coupled Receptors (GPCRs). The company had a fully functional drug discovery platform and a growing portfolio of drug candidates targeting GPCRs for various indications. At the time of acquisition, its most advanced project is a drug called clazosentan (aims to prevent cerebral vasospasm, or sharp contractions of the blood vessels, which can occur after a certain type of brain hemorrhage), which it licensed from Roche Holding AG. The drug was in Phase II of clinical testing, which monitors effectiveness and safety on a limited number of patients, and the same class as Actelions Tracleer.
- Headquarters Allschwil, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website axovan.com
- Acquired by Actelion (Sep 2003)
Funding Insights of Axovan
Axovan has successfully raised a total of $23.31M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $18.4 million completed in April 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.31M
- Total Rounds 2
- Last Round Series B — $18.4M
- First Round $4.91M
(Jun 2000)
- Investors Count 2
All 2 funding rounds of Axovan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2002 | $18.4M | Series B | – | Atlas Venture | – |
| Jun 2000 | $4.91M | Series A | – | Heidelberg Innovationsfonds Management | – |
3 investors in total: 3 institutional.
Investors in Axovan
Axovan has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Actelion, Atlas Venture and Heidelberg Innovationsfonds Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
| hd-innovation.de | ||||
Innovative treatments for orphan diseases are discovered, developed, and commercialized. | 1997 | actelion.com | Allschwil, Switzerland |
Investor details for Axovan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Axovan
4 dated milestones of Axovan across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Axovan is founded.
- Funding First funding round of $4.9M.
- Funding Latest funding round, Series B, of $18.4M.
- Exit Acquired by Actelion.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Axovan
Complete news archive for Axovan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axovan
Axovan was founded in 2000.
Axovan is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.
Axovan is a funded company, having raised a total of $23.31M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4.91M, raised on Jun 2000.
Axovan AG was a drug development company specializing in G Protein-Coupled Receptors (GPCRs). The company had a fully functional drug discovery platform and a growing portfolio of drug candidates targeting GPCRs for various indications. At the time of acquisition, its most advanced project is a drug called clazosentan (aims to prevent cerebral vasospasm, or sharp contractions of the blood vessels, which can occur after a certain type of brain hemorrhage), which it licensed from Roche Holding AG. The drug was in Phase II of clinical testing, which monitors effectiveness and safety on a limited number of patients, and the same class as Actelions Tracleer.
Axovan has 3 investors. Key investors include Actelion, Atlas Venture, and Heidelberg Innovationsfonds Management.
Yes. Axovan was acquired by Actelion in September 2003.